REGULATORY UPDATE: AABB Updates Ebola Toolkit to Reflect FDA’s Latest Recommendations

November 17, 2026

AABB updated its Ebola Toolkit for Evaluation of Blood Donors and the AABB Model DHQ Ebola Questions and Flowcharts to reflect FDA’s latest recommendations regarding Ebola testing, which state that blood collection facilities may discontinue asking donors about residency in or travel to Uganda. Additional information is available on AABB’s Evaluating Donors for Risk of Ebola Disease page.

The latest FDA communication states that, based on the absence of active cases of Ebola disease in Uganda, blood collection facilities are no longer required  to assess donors for residency in, or travel to, Uganda. However, the recommendation to assess donors for residency in or travel to the Democratic Republic of the Congo (DRC) remains in effect. Blood collection facilities should continue to assess donors for residency in or travel to the DRC and defer donors who have resided in or traveled to the DRC for at least eight weeks following departure from the DRC, in accordance with section III.B.2 of FDA’s June 2026 Ebola Guidance and 21 CFR 630.10(e)(2).

The supporting information for the Model DHQ Ebola questions and flowcharts is now country-neutral, and will not require revision when FDA changes the list of countries for which donor residency and travel history should be assessed. Blood establishments should refer to FDA’s most recent Safety and Availability Communication for the current list. The updated Toolkit retains the country-specific language and history of FDA’s June 29 and October 22 communications.

Discontinuing assessment for Uganda is permitted but not required. Blood collection facilities may adopt more restrictive donor eligibility criteria than FDA recommends.

AABB members with additional questions are invited to contact regulatory@aabb.org.